These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33676198)

  • 1. Genetic testing and genetic discrimination: Public policy when insurance becomes "too expensive".
    Posey LL; Thistle PD
    J Health Econ; 2021 May; 77():102441. PubMed ID: 33676198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous information, adverse selection, and prevention: Implications for genetic testing policy.
    Peter R; Richter A; Thistle P
    J Health Econ; 2017 Sep; 55():95-107. PubMed ID: 28774725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse selection and categorical discrimination in the health insurance markets: the effects of genetic tests.
    Strohmenger R; Wambach A
    J Health Econ; 2000 Mar; 19(2):197-218. PubMed ID: 10947576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insurance underwriting in the genetic era.
    Pokorski RJ
    Am J Hum Genet; 1997 Jan; 60(1):205-16. PubMed ID: 8981964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insurance for the insurers. The use of genetic tests.
    Kass NE
    Hastings Cent Rep; 1992; 22(6):6-11. PubMed ID: 1428853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Japanese insurers' attitudes toward adverse selection and genetic discrimination: a questionnaire survey and interviews with employees about using genetic test results.
    Iida H; Muto K
    J Hum Genet; 2021 May; 66(5):539-542. PubMed ID: 33177703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics and the British insurance industry.
    Cook ED
    J Med Ethics; 1999 Apr; 25(2):157-62. PubMed ID: 10226922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic screening technology: ethical issues in access to tests by employers and health insurance committees.
    Faden RR; Kass NE
    J Soc Issues; 1993; 49(2):75-88. PubMed ID: 17165239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic screening, health care and the insurance industry. Should genetic information be made available to insurers?
    Ossa DF; Towse A
    Eur J Health Econ; 2004 Jun; 5(2):116-21. PubMed ID: 15452747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic testing and the social responsibility of private health insurance companies.
    Jecker NS
    J Law Med Ethics; 1993; 21(1):109-16. PubMed ID: 11652117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scope and Incentives for Risk Selection in Health Insurance Markets With Regulated Competition: A Conceptual Framework and International Comparison.
    van Kleef RC; Reuser M; McGuire TG; Armstrong J; Beck K; Brammli-Greenberg S; Ellis RP; Paolucci F; Schokkaert E; Wasem J
    Med Care Res Rev; 2024 Jun; 81(3):175-194. PubMed ID: 38284550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of U. S. state insurance commissioners concerning genetic testing and life insurance: Redux at 27.
    Golinghorst DR; Prince AER
    J Genet Couns; 2020 Dec; 29(6):928-935. PubMed ID: 31850620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How is the trade-off between adverse selection and discrimination risk affected by genetic testing? Theory and experiment.
    Bardey D; De Donder P; Mantilla C
    J Health Econ; 2019 Dec; 68():102223. PubMed ID: 31581025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model to decompose the performance of supplementary private health insurance markets.
    Leidl R
    Int J Health Care Finance Econ; 2008 Sep; 8(3):193-208. PubMed ID: 18568435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs, commitment and locality: a comparison of for-profit and not-for-profit health plans.
    Inquiry; 2004; 41(2):116-29. PubMed ID: 15449428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can the regulator show evidence of (no) risk selection in health insurance markets? Conceptual framework and empirical evidence.
    van de Ven WP; van Vliet RC; van Kleef RC
    Eur J Health Econ; 2017 Mar; 18(2):167-180. PubMed ID: 26837411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community concerns about genetic discrimination in life insurance persist in Australia: A survey of consumers offered genetic testing.
    Tiller J; Bakshi A; Dowling G; Keogh L; McInerney-Leo A; Barlow-Stewart K; Boughtwood T; Gleeson P; Delatycki MB; Winship I; Otlowski M; Lacaze P
    Eur J Hum Genet; 2024 Mar; 32(3):286-294. PubMed ID: 37169978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic predictive testing and private insurances.
    Abbing HD
    Health Policy; 1991 Aug; 18(3):197-206. PubMed ID: 10114501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic discrimination in health insurance--comprehensive legal solutions for a (not so) special problem?
    Rich RF; Ziegler J
    Indiana Health Law Rev; 2005; 2(1):1-47. PubMed ID: 17111499
    [No Abstract]   [Full Text] [Related]  

  • 20. Why disclosure of genetic tests for health insurance should be voluntary.
    Smith R; Raithatha N
    J Health Serv Res Policy; 2006 Jul; 11(3):184-6. PubMed ID: 16824267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.